Unexpected Hepatotoxicities in Patients with Non-Hodgkin's Lymphoma Treated with Irinotecan (CPT-11) and Etoposide

Japanese Journal of Clinical Oncology

Volumn 28, Issue 8, 1998, Pages 502-506

  Ohtsu, Tomoko ^a   Sasaki, Yasutsuna ^a   Igarashi, Tadahiko ^a   Murayama, Tohru ^b   Kobayashi, Yukio ^b   Tobinai, Kensei ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

CPT 11; Etoposide; Hepatotoxicity; Non hodgkin's lymphoma

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ETOPOSIDE; IRINOTECAN;

ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; HUMAN; LIVER; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; HUMANS; LIVER; LYMPHOMA, NON-HODGKIN; MIDDLE AGED;

EID: 0032135729     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.8.502     Document Type: Article

References (24)

1. Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, et al. 7-Ethyl-10-[4-(1-pipendino)-1 -piperidino]carbonyloxycamptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol 1994:34:5112-7.
2. Saijo N. Clinical trials of innotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan. Ann N Y Acad Sci 1996;803:292-305.
3. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996;74:327-38.
4. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11 : a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990:8:1907-12.
5. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. A late phase II trial of a potent topoisomerase I inhibitor. CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 1992:11:36.
6. Tobinai K, Hotta T, Saito H, Ohnishi K, Ohno R, Ogura M, et al. Combination phase I/II study of irinotecan hydrochloride (CPT-II) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1996:26:455-60.
7. Tsurno T, Matsuzaki T, Matsushima M, Saito H, Yokokura T, Anti-tumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988:21:71-4.
8. Sugimoto Y, Tsukahara S, Oh-hara T, F-Liu L, Tsuruo T. Elevated expression of DNA topoisoraerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990:50.7962-5.
9. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomeiase I and II in human tumor xenografts in nude mice. Int J Cancer 1992:50:760-6.
10. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Canter 1992:50:604-10.
11. Moriyama Y, Shibata A, Maekawa I, Yoshida Y, Miura A, Wakui A, et al. A phase II trial of etoposide (VP-16) administered intravenously for the treatment of malignant lymphoma and acute leukemia. Rinsho Ketsueki Gakkai Zasshi 1985:26:1774-84 (in Japanese).
12. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takcyama K. et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993:23:250-7.
13. World Health Organization WHO Hand Book for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
14. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990:50:1715-20.
15. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer 1982;49:2112-35.
16. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K. et al. Phase I study of weekly intravenous infusions of camptothecin. in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991:83:1164-8.
17. Wakui A, Yokoyama M, Takahashi H, Yoshida Y, Sakata Y, Sato S, et al A phase I study of VP-16-213 (VP, etoposide) by a single and 5-day intravenous administration. Can to Kagakuryoho 1986:13:319-29 (in Japanese).
18. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ Metabolic fate of innotecan in humans: correlation of glucuronidation. Cancer Res 1994:54:3723-5
19. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993:85.271-91.
20. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Concer Inst 1992;84.972-4.
21. Karato A, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors J Clin Oncol 1993;11:2030-5.
22. Oshita F, Noda K, Nishiwaki Y, Fujita Y, Kurita Y, Nakabayashi T, et al. Phase LI study of irrinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1997;15:304-9.
23. Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, et al. Phase I and pharmacologic study of irrinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994;12:1833-41.
24. Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, et al. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Canter 1997:11:1494-9.